Movement Alert｜Duality Biotherapeutics-B Rises 15.01% in Regular Trading, ADC Sector Breakthrough and Biotech Rebound Drive Surge

Market Focus07-02 10:21

On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.

On the news front, the domestic ADC sector has achieved concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving market approval, highlighting the leading advantage of Chinese companies. Additionally, the company's A-share IPO application for the SSE STAR Market has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug R&D, significantly boosting capital market attention.

At the industry level, the biotech sector rallied broadly, with 3SBIO up 10.72%, Akeso up 8.74%, Kelun-Biotech up 8.44%, and Innovent Biologics up 8.04%, reflecting strong sector-wide momentum. The company has also been actively conducting share buybacks and its founder previously announced plans to increase holdings, reinforcing confidence in intrinsic value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192849276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192849276","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 15.01% in Regular Trading, ADC Sector Breakthrough and Biotech Rebound Drive Surge","media":"Market Focus","content":"<p><p>On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.</p><p>On the news front, the domestic ADC sector has achieved concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving market approval, highlighting the leading advantage of Chinese companies. Additionally, the company's A-share IPO application for the SSE STAR Market has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug R&D, significantly boosting capital market attention.</p><p>At the industry level, the biotech sector rallied broadly, with 3SBIO up 10.72%, Akeso up 8.74%, Kelun-Biotech up 8.44%, and Innovent Biologics up 8.04%, reflecting strong sector-wide momentum. The company has also been actively conducting share buybacks and its founder previously announced plans to increase holdings, reinforcing confidence in intrinsic value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 15.01% in Regular Trading, ADC Sector Breakthrough and Biotech Rebound Drive Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 15.01% in Regular Trading, ADC Sector Breakthrough and Biotech Rebound Drive Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.</p><p>On the news front, the domestic ADC sector has achieved concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving market approval, highlighting the leading advantage of Chinese companies. Additionally, the company's A-share IPO application for the SSE STAR Market has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug R&D, significantly boosting capital market attention.</p><p>At the industry level, the biotech sector rallied broadly, with 3SBIO up 10.72%, Akeso up 8.74%, Kelun-Biotech up 8.44%, and Innovent Biologics up 8.04%, reflecting strong sector-wide momentum. The company has also been actively conducting share buybacks and its founder previously announced plans to increase holdings, reinforcing confidence in intrinsic value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1192849276","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192849276","pubTimestamp":1782958918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.On the news front, the domestic ADC sector has achieved...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|Duality Biotherapeutics-B常规交易涨15.01%ADC板块突破生物科技反弹带动大涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 2, Duality Biotherapeutics-B rose 15.01% in regular trading, trading at HKD 208.2 per share, with turnover of HKD 209 million.On the news front, the domestic ADC sector has achieved concentrated breakthroughs recently, with the world's first bispecific antibody ADC receiving market approval, highlighting the leading advantage of Chinese companies. Additionally, the company's A-share IPO application for the SSE STAR Market has been accepted by the Shanghai Stock Exchange, with plans to raise RMB 4.1 billion for new drug R&D, significantly boosting capital market attention.At the industry level, the biotech sector rallied broadly, with 3SBIO up 10.72%, Akeso up 8.74%, Kelun-Biotech up 8.44%, and Innovent Biologics up 8.04%, reflecting strong sector-wide momentum. The company has also been actively conducting share buybacks and its founder previously announced plans to increase holdings, reinforcing confidence in intrinsic value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192849276","isCrawlerRequest":true}